ÂÜÀòÂÒÂ×

Liang (Kevin) Chen has been working in the healthcare industry since 2007. Liang (Kevin) began their career as a Research Assistant in the Hematology & Oncology Department at Xi'an Jiaotong University. In 2009, they became a Research Assistant at the Feigon (NAS Member) Lab at UCLA Department of Chemistry and Biochemistry. In 2010, they worked as a Research Scientist in Computational Biochemistry for Drug Design at the Chinese Academy of Sciences. In 2011, they became a Graduate Research Assistant in Cancer Pharmacology at NYU Langone Health. In 2013, they worked as a Medical Specialist in Neuroscience at Johnson & Johnson. In 2014, they worked as a Product Manager in Multiple Cancer Areas at Pfizer. In 2016, they became a Avastin® Product Manager in Lung Cancer Franchise Launch at Roche. In 2019, they worked as an Incubation: Strategy of Oncology Early Clinical Development at Everest Medicines. Liang (Kevin) was trained by CEO (ex-Eli Lilly CSO) Dr. Kerry Blanchard and co-created the early clinical development strategy (pre-POC stage) of Trodelvy (world's first anti-Trop2 ADC) and FGFR4 inhibitor. In 2018, they worked at CBC Group as a Vice President, Assistant Vice President, and Associate. In 2021, they became the Co-Founder, Head of Strategy & Corporate Development at Ensem Therapeutics.

Liang (Kevin) Chen began their educational journey in 2006 when they obtained a BE in BioEngineering from Xi'an Jiaotong University, with a research focus in Hematology & Oncology. In 2009, they were a Research Scholar in the CSST Program at the University of California, Los Angeles, studying Structural Biology. The following year, they were a Research Scholar at the Chinese Academy of Sciences, studying Computational Biochemistry For Drug Design. From 2011 to 2013, they attended NYU Grossman School of Medicine, where they obtained an MS in Research Program, specializing in Cancer Pharmacology & Toxicology. Liang (Kevin) is currently enrolled in a Certificate Program at the Massachusetts Institute of Technology, studying Machine Learning, Modeling, and Simulation: Engineering Problem-Solving in the Age of AI, which they are expected to complete in 2022.